
New details show that a 40-year-old businessman flew and crossed regional borders while seriously ill, apparently without being identified as a possible Ebola case.
8:00 PMBBC19 stories from 8 sources
Supporting Articles

New details show that a 40-year-old businessman flew and crossed regional borders while seriously ill, apparently without being identified as a possible Ebola case.
8:00 PMBBC
The federal government released Medicare Advantage quality ratings for 2027, with Humana positioned as the largest beneficiary of the resulting bonuses. The ratings also create uncertainty for insurers whose payments may change with their scores.
11:55 AMStat NewsNo Medicare Advantage plans will be available in 181 counties in 2027, up from 67 counties in 2026. Residents in those areas will face fewer private-plan choices during open enrollment.
11:01 AMMarketWatchFlu season began about seven weeks earlier than it did in 2025 or 2024. The early start puts vaccination timing and preparedness under pressure as infections begin circulating sooner.
2:01 PMMarketWatch
The war has forced carriers to reroute contraceptive shipments to African clinics, adding months to delivery times. The disruption compounds a $185 million funding shortfall and broader reductions in foreign aid.
10:00 AMFortune
The American Hospital Association is again challenging the Trump administration's plan to restructure the 340B drug discount program. The pilot would replace upfront discounts for participating hospitals with rebates paid after drugs are purchased.
4:27 PMStat News
Summary
New details show that a 40-year-old businessman flew and crossed regional borders while seriously ill, apparently without being identified as a possible Ebola case.
The central failure was not only the patient’s travel, but the breakdown of screening and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Undetected cross-border travel can turn a single Ebola case into a regional public-health threat.

Summary
The federal government released Medicare Advantage quality ratings for 2027, with Humana positioned as the largest beneficiary of the resulting bonuses. The ratings also create uncertainty for insurers whose payments may change with their scores.
The ratings convert measured quality performance into a direct financial advantage for Humana and other
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The ratings will shape insurer revenue and could influence the benefits and plan choices available to Medicare Advantage members.
2 stories · 2 sources
Summary
No Medicare Advantage plans will be available in 181 counties in 2027, up from 67 counties in 2026. Residents in those areas will face fewer private-plan choices during open enrollment.
The withdrawal of plans makes local Medicare markets less competitive and can force beneficiaries to
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Millions of beneficiaries may face higher costs, narrower choices, or disruptive plan changes as Medicare Advantage availability contracts.
Summary
Flu season began about seven weeks earlier than it did in 2025 or 2024. The early start puts vaccination timing and preparedness under pressure as infections begin circulating sooner.
The key shift is timing: people and health systems have less lead time than in
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
An unusually early season can increase illness before communities and clinics are fully prepared.

Summary
The war has forced carriers to reroute contraceptive shipments to African clinics, adding months to delivery times. The disruption compounds a $185 million funding shortfall and broader reductions in foreign aid.
Supply delays are colliding with a financing crisis, leaving clinics vulnerable to stockouts and interruptions
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A logistics shock could quickly become a reproductive-health crisis by increasing unmet need and disrupting routine family-planning services.

Summary
The American Hospital Association is again challenging the Trump administration's plan to restructure the 340B drug discount program. The pilot would replace upfront discounts for participating hospitals with rebates paid after drugs are purchased.
The lawsuit keeps the administration's 340B redesign tied up in a legal and operational fight.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The dispute could change how safety-net hospitals finance discounted medicines and manage billions of dollars in drug costs.
A curated list of other prominent stories from this day.

Bambusa Therapeutics filed for an initial public offering to fund clinical trials of treatments for eczema and other inflammatory disorders.
6:06 PMBloomberg Markets
Steven Quay, a biopharmaceutical executive without an infectious-disease background and a prominent advocate of the lab-leak theory, is no longer being considered to lead the National Institute of Allergy and Infectious Diseases.
5:03 PMStat News
A new review found that gifts and payments from drugmakers were associated with more inappropriate prescribing by physicians. The analysis suggests these interactions may also raise health care spending.
12:33 PMStat News
Life Biosciences reported that three glaucoma patients have received a single injection of its experimental cellular reprogramming drug. No serious adverse events have been reported so far.
11:41 AMStat News
The FDA approved Teva's Weltruza, a once-monthly injectable treatment for schizophrenia. Teva shares gained in premarket trading after the announcement.
9:14 AMCNBC
New cystic fibrosis medicines have transformed care for most patients, but roughly 10% cannot benefit from them. Emily's Entourage is funding research aimed at developing treatments for this remaining group.
7:43 AMCNBC
Melinda French Gates says women's health remains substantially underserved, with Gallup-Pivotal research showing that more than four in ten women in the UK say health problems have limited their lives. More than half of US women also reported a negative healthcare experience in the past five years, alongside persistent gaps in information and care.
7:02 AMBloomberg Markets
A six-month study found that high-intensity interval training helped older adults reduce body fat while preserving muscle. Moderate-intensity exercise produced a small loss of lean muscle despite improving body composition.
6:57 AMScienceDaily
Proposed changes to the U.S. census could eliminate or weaken data used to measure health disparities, argues social epidemiologist Nancy Krieger. She warns that removing categories from official statistics would not remove the underlying needs or harms.
4:30 AMStat News
Researcher Betsy Pleasants used Reddit posts to study how the fall of Roe changed abortion access and the barriers patients encountered. Her work also develops a framework for using AI in social research while preserving the experiences behind the data.
4:30 AMStat NewsHospital stocks rose after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, a move that could reduce medicine prices by as much as 70%. Jefferies and Emkay expect the earnings impact to remain manageable, while Jefferies favors Fortis, Manipal, Apollo, Max Healthcare and Medanta.
1:44 AMEconomic Times
Russian authorities completed precautionary measures after an employee at the Irkutsk Anti-Plague Institute died. Nearly 5,000 laboratory tests found no dangerous pathogens, including plague.
1:04 AMBloomberg Markets
Summary
Bambusa Therapeutics filed for an initial public offering to fund clinical trials of treatments for eczema and other inflammatory disorders.
The filing gives Bambusa access to public-market capital but also exposes the company to dilution
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The IPO tests whether investors will fund early-stage inflammation drugs despite substantial clinical and commercialization risk.

Summary
Steven Quay, a biopharmaceutical executive without an infectious-disease background and a prominent advocate of the lab-leak theory, is no longer being considered to lead the National Institute of Allergy and Infectious Diseases.
Quay's removal narrows the controversy around the appointment and reduces the likelihood that the agency
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The leadership choice will influence NIAID's scientific credibility, research priorities, and public standing.

Summary
A new review found that gifts and payments from drugmakers were associated with more inappropriate prescribing by physicians. The analysis suggests these interactions may also raise health care spending.
The finding challenges the idea that small industry-sponsored benefits are harmless or merely educational. If
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Reducing low-value prescribing could improve patient safety while lowering avoidable drug costs.

Summary
Life Biosciences reported that three glaucoma patients have received a single injection of its experimental cellular reprogramming drug. No serious adverse events have been reported so far.
The immediate signal is early safety, not proof of benefit: the study has treated only
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The treatment is an early test of whether cellular reprogramming can be used safely in human eye disease.

Summary
The FDA approved Teva's Weltruza, a once-monthly injectable treatment for schizophrenia. Teva shares gained in premarket trading after the announcement.
The approval gives Teva a new long-acting product in a market where fewer dosing days
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A monthly treatment could expand Teva's growth prospects while offering patients a less frequent dosing option.

Summary
New cystic fibrosis medicines have transformed care for most patients, but roughly 10% cannot benefit from them. Emily's Entourage is funding research aimed at developing treatments for this remaining group.
The decisive gap is that advances in precision treatment have left patients with certain disease-causing
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A major medical breakthrough remains incomplete if the patients whose mutations fall outside current therapies have no path to benefit.

Summary
Melinda French Gates says women's health remains substantially underserved, with Gallup-Pivotal research showing that more than four in ten women in the UK say health problems have limited their lives. More than half of US women also reported a negative healthcare experience in the past five years, alongside persistent gaps in information and care.
The data points to failures across the healthcare system, not a single disease or life
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Women's health deficits are limiting lives at scale and exposing a broader failure in how healthcare allocates attention and resources.

Summary
A six-month study found that high-intensity interval training helped older adults reduce body fat while preserving muscle. Moderate-intensity exercise produced a small loss of lean muscle despite improving body composition.
The key finding is a tradeoff between fat loss and muscle preservation, with HIIT performing
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A workout strategy that limits muscle loss could improve how clinicians approach weight management in aging adults.

Summary
Proposed changes to the U.S. census could eliminate or weaken data used to measure health disparities, argues social epidemiologist Nancy Krieger. She warns that removing categories from official statistics would not remove the underlying needs or harms.
The immediate shift is from documenting inequity to making parts of it harder to see.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Less complete census data could translate into less effective health policy and reduced accountability for unequal outcomes.

Summary
Researcher Betsy Pleasants used Reddit posts to study how the fall of Roe changed abortion access and the barriers patients encountered. Her work also develops a framework for using AI in social research while preserving the experiences behind the data.
The key change is that abortion barriers became more geographically and logistically complex after Roe,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Understanding abortion access now requires tracking lived barriers that formal healthcare and administrative data may not capture.
Summary
Hospital stocks rose after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, a move that could reduce medicine prices by as much as 70%. Jefferies and Emkay expect the earnings impact to remain manageable, while Jefferies favors Fortis, Manipal, Apollo, Max Healthcare and Medanta.
The margin cap shifts value toward patients and hospitals while pressuring drug-related margins in the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The policy could improve cancer treatment affordability without materially weakening hospital earnings.

Summary
Russian authorities completed precautionary measures after an employee at the Irkutsk Anti-Plague Institute died. Nearly 5,000 laboratory tests found no dangerous pathogens, including plague.
The testing has sharply reduced the risk of an infectious outbreak linked to the death,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The results ease immediate public-health concerns but leave the underlying fatality unresolved.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!